Use of infliximab in the treatment of Crohn's disease in children and adolescents.
about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitisInterventions for growth failure in childhood Crohn's diseaseExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesEfficacy of early treatment with infliximab in pediatric Crohn's disease.Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Review article: the limitations of corticosteroid therapy in Crohn's disease.Change in the treatment strategy for pediatric Crohn's diseaseThe apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis.Infliximab therapy in pediatric Crohn's disease: a review.Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.Treatment of inflammatory bowel disease in childhood: best available evidence.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Maintenance of remission in Crohn's disease.Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management.New patients: should children be treated differently?Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.Recent advances in the medical therapy of Crohn's disease in childhood.Infliximab therapy for pediatric Crohn's disease.Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseT-cell-directed therapies in inflammatory bowel diseases.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy.Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.Successful treatment of pediatric psoriasis with infliximab.Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.Niemann-pick disease type C and Crohn's disease.“New drugs: Kids come first”: Children should be included in trials of new biological treatments
P2860
Q22242050-9914F2A3-094F-46D9-AC98-244279A8213DQ24245033-01B30211-5955-463E-8F3A-32738189470EQ24246404-E80EC9BB-4EEC-4221-8847-A6D2CAEF06F5Q28066776-FCE10ED7-30B5-460E-97F8-D39ABAA864B4Q33782089-62E68495-A713-4209-BAC5-6423CDA6720EQ33798912-1404D409-8C85-4D1E-A1EA-E572B62FB733Q34152778-661C4B48-02DC-499B-8497-6BC0A6515435Q34374135-92F1F606-3431-47EA-8BC5-C6C0877C7820Q34420755-4F901FB3-0DE6-4EBB-93F4-531932FAC9ECQ34537041-C4B1588D-558D-484B-9950-F62139FEBE37Q35026358-1D1FB17F-AE77-436B-8EF2-F98FD9606AC2Q35030557-217CBCFA-6E9E-476E-8B86-22A8D10094FAQ35044599-C7836BDD-E0BF-4C38-89F6-B54FC37B08DFQ35091746-E72B78C1-B24A-4A47-A175-E86AAA6BA925Q35116177-01D34EB8-1A14-4F91-BC94-220901F80728Q36041732-93272842-8315-4B96-9CF6-42E4A55397EDQ36171739-A81F4E64-17F5-49AF-B8A9-61D1EB3C57D7Q36440544-D288FCD2-6BB5-437B-A4BA-2BD30E3BA81DQ36881309-5103864D-9855-42F8-AD08-B0167737E0C5Q36968175-5170F3FD-E27E-4DD1-8045-28ED08FDE859Q37012073-16A52B19-0DCB-41B1-90C9-0B177168C99CQ37101534-73F9F9CD-EC33-4420-A251-BDCE36A969BCQ37609746-A20F6AFC-E591-4DBA-AD1B-1C17FA4F4222Q37720783-51238467-4680-4FA9-A778-D3DE07465CA5Q37820898-4114F893-0557-47CA-8295-E4A45A7BF606Q37936394-9F157A1A-6E23-45C5-8019-C073A0947F8BQ39114030-D1D6F7BE-B8A8-4982-B4D9-A7DD71AF7F85Q39539435-8D25797A-6C7E-4626-8761-E567F1646DB8Q42032750-39D0D0DF-B172-4A15-B33F-492EAA1B5252Q43633425-D0A991CA-05AE-465C-9DC7-C146E2441D8DQ46234832-9BDEF11D-FDF5-4CE5-B044-DC89D0894887Q51052619-A49A4860-69A2-4E00-9CDE-AFAC154679E5Q51509683-3BBD71C3-A73C-4063-96D2-D864703D9F36Q53292298-E92BF77C-4F3F-4AF4-A091-F837145E315AQ57804309-382379B4-A834-445C-9785-8489E3ED3468
P2860
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@ast
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@en
type
label
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@ast
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@en
prefLabel
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@ast
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@en
P2093
P356
P1476
Use of infliximab in the treatment of Crohn's disease in children and adolescents.
@en
P2093
P304
P356
10.1067/MPD.2000.107161
P407
P577
2000-08-01T00:00:00Z